EUVIMEDEUVIMED entdecken
Crossref

1702-P: Molecular Basis of Type 2 Diabetes Prevention by Semaglutide in SELECT

DYLAN M. BELMONT-RAUSCH, ALEJANDRO AGUAYO OROZCO, WEI GAN, GERMAN D. CARRASQUILLA, MARIA QUIROGA, ILDIKO LINGVAY, STEVEN KAHN, JONATHAN PURNELL, LOTTE BJERRE KNUDSEN

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-1702-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von DYLAN M. BELMONT-RAUSCH und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: In the randomized SELECT trial, semaglutide (sema) reduced the risk of developing T2D by 73% vs placebo. The molecular mechanisms underlying the delay in progression to biochemical diabetes remain poorly understood.

Methods

A post hoc analysis of SELECT participants (pts) with proteomics (SomaScan 7k) included 7209 pts with prediabetes (HbA1c ≥5.7-6.4%), overweight/obesity, and established cardiovascular disease. Pts received once-weekly sema (n=3609) or placebo (n=3600). Baseline proteomics were analyzed to identify proteins prognostic for T2D progression at week 104. Mediation analysis assessed if these proteins mediated sema's preventive effect. Genetic evidence was used to triangulate causal roles of these proteins.

Results

Of pts with prediabetes, 19 (0.5%) on sema and 213 (6%) on placebo progressed to T2D. Of the 26 proteins prognostic for T2D progression, sema favorably modulated 21, with 18 mediating up to 8% of its effect (Figure). Among all proteins mediating sema's effect, 32 had genetic evidence for causal roles in T2D.

Conclusion

Sema prevents T2D progression through multiple pathways, including hepatic lipid handling. By integrating clinical biomarkers, proteomic profiling, and genetic causal inference, we identified 32 proteins that mediate T2D prevention by sema. The mechanisms by which changes in protein levels mediate the effect are being investigated further. Disclosure D.M. Belmont-Rausch: Employee; Current; Novo Nordisk A/S. Stock/Shareholder; Current; Viking Therapeutics. Stock/Shareholder; Ended; Madrigal Pharmaceuticals, Inc. A. Aguayo Orozco: Employee; Current; Novo Nordisk. W. Gan: Employee; Current; Novo Nordisk A/S, Novo Nordisk. G.D. Carrasquilla: Employee; Current; Novo Nordisk A/S. M. Quiroga: Employee; Current; Novo Nordisk. Stock/Shareholder; Current; Eli Lilly and Company, Genmab, Coloplast, Novo Nordisk. I. Lingvay: Consultant; Current; Aadvarak Therapeutics, Abbvie, Alveus Therapeutics, Amgen, Antag Therapeutics, Arrowhead Pharmaceuticals, Astra Zeneca, Baim Institute, Bain Capital, Bayer, Betagenon AB, Bioio Inc., Biomea, Boehringe. Research Support; Current; Novo Nordisk A/S, Dexcom, Inc., Boehringer Ingelheim International GmbH. Consultant; Current; Eli Lilly, Genentech, Janssen/J&J, Juvena, Keros Therapeutic, Inc, Mediflix, Metsera, Neurocrine, Novo Nordisk, Penguin Bio, Pfizer, Regeneron, Response Pharmaceutical, Roche, Sanofi, Shionogi, Skye B, Tenvie, TERNS Pharma, Verdiva Bio, Viking Therapeutics, and Zealand Pharma. S. Kahn: Advisory Panel; Current; AltPep, Amgen Inc., Congruence Therapeutics, Eli Lilly and Company, General Medicines, Kayothera, Merck & Co., Inc., Neurimmune, Novo Nordisk, Roche Pharmaceuticals. J. Purnell: Advisory Panel; Current; Boehringer Ingelheim International GmbH, Novo Nordisk. Advisory Panel; Ended; Regeneron Pharmaceuticals Inc. Advisory Panel; Current; Zealand Pharma A/S. L. Bjerre Knudsen: Employee; Current; Novo Nordisk.

Zitieren

APA

BELMONT-RAUSCH, D. M., OROZCO, A. A., GAN, W., CARRASQUILLA, G. D., QUIROGA, M., LINGVAY, I., KAHN, S., PURNELL, J., & KNUDSEN, L. B. (2026). 1702-P: Molecular Basis of Type 2 Diabetes Prevention by Semaglutide in SELECT. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1702-p

Vancouver

BELMONT-RAUSCH DM, OROZCO AA, GAN W, CARRASQUILLA GD, QUIROGA M, LINGVAY I, et al. 1702-P: Molecular Basis of Type 2 Diabetes Prevention by Semaglutide in SELECT. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1702-p

BibTeX
@article{BELMONTRAUSCH2026,
  author = {BELMONT-RAUSCH, DYLAN M. and OROZCO, ALEJANDRO AGUAYO and GAN, WEI and CARRASQUILLA, GERMAN D. and QUIROGA, MARIA and LINGVAY, ILDIKO and KAHN, STEVEN and PURNELL, JONATHAN and KNUDSEN, LOTTE BJERRE},
  title = {1702-P: Molecular Basis of Type 2 Diabetes Prevention by Semaglutide in SELECT},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-1702-p}
}
Kostenlos starten →